Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
DTIL Catalyst Timeline
Dated clinical, regulatory and corporate events for Precision BioSciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Precision BioSciences, Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How DTIL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-08 | PBGENE-HBV | Phase 1 data presentation | Phase 1 |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PBGENE-DMD Gene TherapiesNCT07429240 | Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD | Phase 1/2 | RECRUITING | 18 | Dec 1, 2029 | ||||||
| PBGENE-HBV Gene TherapiesNCT06680232 | HEPATITIS B CHRONIC | Phase 1 | RECRUITING | 45 | Jun 1, 2027 | ||||||
| PBCAR19B Cell TherapiesCompletedNCT04649112 | CD19 Expressing Malignancies | Phase 1 | COMPLETED | 13 | Sep 30, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every DTIL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| PBGENE-HBV Fast Track | chronic hepatitis B | Phase 1 | 2026-11-05 | 100% pgRNA loss in evaluable patients at a 0.4 mg/kg dose; Durable and ongoing pgRNA loss in 100% of patients with ≥6 months of follow-up; 1-log and 1.5-log reduction in cccDNA at 0.4 mg/kg; Treatment effect observed in 100% of evaluable patients as measured by HBsAg reductionRead More | Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral CureRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Scimeca DarioOfficer (Chief Legal Officer) | Sell | -2,821 56,782 held | $9.75 | 11/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DTIL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 0.5 % | 5.24 M | 836.76 K |
Ownership Trends
DTIL Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How DTIL ranks across every disease it competes in
DTIL News
Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Precision BioSciences announced a $125 million underwritten offering of common stock and pre-funded warrants. The offering includes 10,235,077 shares priced at $7.75 each and warrants for 5,893,964 shares. The funds will be used for ongoing research and development of gene editing therapies. The offering is expected to close on November 6, 2026.
Read more →Precision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study
Precision BioSciences announced that the independent Data Safety Monitoring Board (DSMB) has completed a safety review of PBGENE-DMD. The first patient treated showed no safety concerns, allowing for additional patient dosing in the Phase 1/2 FUNCTION-DMD study. This trial aims to evaluate the safety and efficacy of PBGENE-DMD for Duchenne muscular dystrophy.
Read more →Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure
Precision BioSciences announced successful Phase 1 data for PBGENE-HBV, achieving 100% pgRNA loss in evaluable patients at a 0.4 mg/kg dose. The treatment demonstrated a well-characterized safety profile and significant reductions in cccDNA. The company plans to advance to a global Phase 2 study to evaluate cure rates in chronic hepatitis B patients.
Read more →Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences reported its third quarter 2026 results, highlighting the dosing of the first patient in the FUNCTION-DMD study. The company also announced a late-breaking presentation for its PBGENE-HBV trial at the upcoming AASLD meeting. With a cash balance of $108 million, Precision expects to fund operations through 2028.
Read more →Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026
Precision BioSciences, Inc. will report its third quarter 2026 financial results on November 3, 2026. The company focuses on developing in vivo gene editing therapies using its proprietary ARCUS platform. This platform aims to provide defined therapeutic outcomes for various genetic and infectious diseases.
Read more →Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026
Precision BioSciences has announced its selection for a late-breaking oral presentation at The Liver Meeting 2026. This prestigious event, organized by the American Association for the Study of Liver Diseases, will occur from November 5-9 in Denver. The presentation will focus on their PBGENE-HBV program, showcasing their ARCUS® gene editing technology.
Read more →Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
Precision BioSciences has initiated dosing in its Phase 1/2 FUNCTION-DMD clinical trial, focusing on PBGENE-DMD for Duchenne muscular dystrophy. This program aims to address a significant unmet medical need in the treatment of DMD. The trial marks a critical step in evaluating the efficacy of their gene editing therapy.
Read more →Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences reported its second quarter financial results for 2026, highlighting a significant milestone in the hepatitis B field with the first clinical biopsy evidence supporting its therapeutic approach. The company continues to advance its proprietary ARCUS platform for gene editing therapies targeting high unmet medical needs. Overall, the financial performance reflects positive growth and progress in its clinical initiatives.
Read more →Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
Precision BioSciences, Inc. has announced it will report its financial results for the second quarter of 2026 on August 6, 2026. The company is focused on developing in vivo gene editing therapies using its proprietary ARCUS® platform. This announcement reflects the company's commitment to transparency and ongoing business operations.
Read more →Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones
Precision BioSciences has announced significant changes to its senior leadership team to enhance the advancement of its clinical programs. Alex Kelly has been promoted to Chief Operating Officer, a new role aimed at overseeing customer-facing functions. These changes are intended to support the company's strategic goals and address high unmet medical needs.
Read more →Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences has announced the approval of inducement awards for new employees under its 2021 Employment Inducement Incentive Award Plan. This decision, made by the Compensation Committee of the Board of Directors, reflects the company's commitment to attracting talent as it continues to develop its ARCUS platform for gene editing therapies.
Read more →Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors
Precision BioSciences has been included in the Russell 2000® Index, which is expected to enhance its market visibility and attract institutional investors. This inclusion reflects the company's growth and stability in the biopharma sector. The move is anticipated to bolster investor confidence and expand the company's reach.
Read more →Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
Precision BioSciences has announced new and late-breaking clinical data from the PBGENE-HBV study during the European Association for the Study of the Liver Congress 2026. The details of the data and its implications for HBV treatment were highlighted, although specifics were not provided in the announcement.
Read more →Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
Precision BioSciences is set to host an investor webcast to discuss the late-breaking data from the PBGENE-HBV trial presented at the European Association for the Study of the Liver Congress 2026. This event will provide insights into the findings and implications of the trial results for stakeholders. Further details about the webcast will be shared as the event approaches.
Read more →Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
Precision BioSciences has presented new preclinical data for PBGENE-DMD at the American Society of Gene & Cell Therapy 2026 Annual Meeting. This advancement supports the transition of the therapy into clinical trials. The presentation highlights the company's ongoing commitment to developing innovative gene therapies.
Read more →Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences has reported its financial results for the first quarter of 2026. The company also provided a business update, although specific details regarding performance or future plans were not disclosed in the article. The report appears to be standard for quarterly financial disclosures.
Read more →Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026
Precision BioSciences, Inc. has announced it will report its financial results for the first quarter of 2026 on May 5, 2026. The company is known for its proprietary ARCUS gene editing platform, which aims to develop therapies for genetic and infectious diseases. This announcement comes as the company continues to work on its clinical stage candidates.
Read more →Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
Precision BioSciences has activated the first clinical trial site for its PBGENE-DMD treatment aimed at Duchenne muscular dystrophy (DMD). The Phase 1/2 FUNCTION-DMD study will evaluate the safety, tolerability, and efficacy of this novel gene editing therapy. Patient enrollment has commenced at Arkansas Children's Hospital, which is recognized for its specialized care in DMD.
Read more →Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
Precision BioSciences announced that new preclinical data from its PBGENE-DMD program will be presented at the ASGCT 2026 Annual Meeting. The data highlights the efficacy of PBGENE-DMD in early-juvenile mice, suggesting potential benefits for younger patients with Duchenne muscular dystrophy. The program aims to improve function in about 60% of DMD patients and has received FDA designations to expedite its development.
Read more →